Cannabinoid 1 (CB1) receptor arrestin subtype‐selectivity and phosphorylation dependence. (6th November 2022)

• Record Type: Journal Article
• Authors: Manning, Jamie J.; Rawcliffe, Gabriel; Finlay, David B.; Glass, Michelle
• Is Part Of: British journal of pharmacology. Volume 180:Number 3(2023)
• Page Start: 369
• Page End: 382
• Publication Date: 2022-11-06
• Subjects: arrestin -- bias -- cannabinoid -- CB1 receptor -- GPCR -- phosphorylation; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15973
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and purpose: Arrestin or G protein bias may be desirable for novel cannabinoid therapeutics. Arrestin‐2 and arrestin‐3 translocation to CB1 receptor have been suggested to mediate different functions that may be exploited with biased ligands. Here, the requirement of a recently described phosphorylation motif ' pxxp ' (where 'p' denotes phosphorylatable serine or threonine and 'x' denotes any other amino acid) within the CB1 receptor C‐terminus for interaction with different arrestin subtypes was examined. Experimental approach: Site‐directed mutagenesis was conducted to generate nine different phosphorylation‐impaired CB1 receptor C‐terminal mutants. Bioluminescence resonance energy transfer (BRET) was employed to measure arrestin‐2/3 translocation and G protein dissociation of a high efficacy agonist for each mutant. Immunocytochemistry was used to quantify receptor expression. Key results: The effects of each mutation were shared for arrestin‐2 and arrestin‐3 translocation to CB1 receptor pxxp motifs are partially required for arrestin‐2/3 translocation, but translocation was not completely inhibited until all phosphorylation sites were mutated. The rate of arrestin translocation was reduced with simultaneous mutation of S425 and S429. Desensitisation of G protein dissociation was inhibited in different mutants proportional to the extent of their respective loss of arrestin translocation. Conclusions and implications: These data do not support the existence of an 'essential' pxxp motif for arrestin translocation to CB1 receptor. These data also identify that arrestin‐2 and arrestin‐3 have equivalent phosphorylation requirements within the CB1 receptor C‐terminus, suggesting arrestin subtype‐selective biased ligands may not be viable and that different regions of the C‐terminus contribute differently to arrestin translocation.